Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the Claims:

Claim 1 (original): An immediate release pharmaceutical composition comprising:

(i) 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically-acceptable salt thereof (the Agent);

(ii) a water-soluble acid; and

(iii) a water-soluble cellulose ether or an ester of a water-soluble cellulose ether.

Claim 2 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 wherein (iii) is ~~comprising the Agent, a water-soluble acid and~~ a water-soluble cellulose ether.

Claim 3 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 wherein (iii) is ~~comprising the Agent, a water-soluble acid and~~ an ester of a water-soluble cellulose ether.

Claim 4 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 or claim 2 wherein the ~~comprising the Agent, a water-soluble acid and a~~ water-soluble cellulose ether is selected from methyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxypropyl methylcellulose.

Claim 5 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 or claim 2 wherein the water-soluble cellulose ether is ~~comprising the Agent, a water-soluble acid and~~ methyl cellulose.

Claim 6 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 or claim 2 wherein the water-soluble cellulose ether is ~~comprising the Agent, a water-soluble acid and~~

hydroxypropyl methylcellulose.

Claim 7 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 or claim 3 wherein the ester of a water-soluble cellulose ether is the ~~comprising the Agent, a water-soluble acid and an~~ ester of hydroxypropyl methylcellulose or the ~~an~~ ester of hydroxypropylcellulose wherein the ester is selected from ~~which carries~~ one or more of ~~ester groups selected from~~ acetate, succinate, phthalate, isophthalate, terephthalate and trimellitate.

Claim 8 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 wherein the ~~or claim 2 comprising the Agent, a water-soluble acid and a~~ water-soluble cellulose ether or the ester of a water-soluble cellulose ether is selected from hydroxypropyl methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose and hydroxypropyl methylcellulose acetate succinate.

Claim 9 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 ~~any one of the preceding claims~~ wherein the water-soluble acid is solid at ambient temperature.

Claim 10 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 ~~any one of the preceding claims~~ wherein the water-soluble acid is a water-soluble aliphatic mono or poly-carboxylic acid which may be saturated or unsaturated.

Claim 11 (currently amended): The ~~A~~ pharmaceutical composition according to claim 10 wherein the water-soluble acid is selected from fumaric acid and malic acid.

Claim 12 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 ~~any one of the preceding claims~~ wherein the molar ratio of Agent to acid is from 1:1 to 1:10.

Claim 13 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 ~~any one of the preceding claims~~ wherein the weight ratio of Agent to water-soluble cellulose ether, or

ester of water-soluble cellulose ether is from 30:1 to 3:1.

Claim 14 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 comprising:

(i) from 10 to 60 parts of the Agent;

(ii) from 2 to 70 parts of a water-soluble cellulose ether selected from methyl cellulose and hydroxypropyl methylcellulose; and

(iii) from 10 to 70 parts of a water-soluble organic acid selected from fumaric acid and malic acid;

wherein all parts are by weight and the sum of the parts (i)+(ii)+(iii)=100; and wherein the molar ratio of Agent to organic acid is from 1:3 to 1:6.

Claim 15 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 wherein ~~any one of the preceding claims which comprises a physical mixture of~~ the Agent, the water-soluble acid, and the water-soluble cellulose ether and/or ester of a water-soluble cellulose ether are a physical mixture.

Claim 16 (currently amended): The ~~A~~ pharmaceutical composition according to claim 15 which is in the form of an oral immediate release tablet, pellet, granule or capsule formulation.

Claim 17 (withdrawn and currently amended): A method for reducing inter-patient and/or intra-patient variability in bioavailability and/or plasma concentrations of the Agent in a patient in need of the Agent comprising orally administering to said patient a pharmaceutical composition according to claim 1 ~~any one of claims 1 to 16, wherein the Agent is as defined in claim 1~~.

Claim 18 (withdrawn and currently amended): A method for increasing the solubilisation of the Agent in an aqueous medium with a pH value similar to those found in the upper GI tract of a human comprising adding to said aqueous medium a pharmaceutical composition according to claim 1 ~~any one of claims 1 to 16,~~ wherein the solubilisation of the Agent from the composition

is increased compared to the solubilisation of the Agent alone in the same aqueous medium~~; and wherein the Agent is as defined in claim 1~~.

Claim 19 (withdrawn and currently amended): A method for inhibiting the rate of precipitation of the Agent from an aqueous solution comprising adding to an aqueous medium with a pH similar to the gastric pH in a human, a pharmaceutical composition according to claim 1 ~~any one of claims 1 to 16; wherein the Agent is as defined in claim 1~~.